AstraZeneca initiates Phase I/II trial of AZD9829 for CD123+ hematological malignancies
AstraZeneca is conducting Phase I/II trial to evaluate AZD9829 in patients with CD123+ hematological malignancies.
Asset / Drug
Drug and asset intelligence for AZD9829 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
CD123-targeted therapy
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.